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Abstract 
Background:  Ensuring the health and safety of the public from adverse reaction of drugs is paramount.  Adverse 
Drug Reactions Monitoring (ADRM) is a system that is put in place to ensure the health and safety of the public from 
adverse reactions of drugs.  It heavily relies on health professionals (HPs) reporting of adverse events of drugs to drug 
regulators, in Ethiopia to the Drug Administration and Control Authority (DACA). The processed information, based 
on reported cases, is used to improve evidence based practice and underpins decisions to mitigate drug safety issues by 
drug regulators. However, the effectiveness of the ongoing ADRM system in Ethiopia in terms of its detection has 
never been evaluated. 
Objective: To explore the magnitude of ADRM and suggest some practical improvement in Ethiopia. 
Methods: The study analyzed the number of adverse drug reaction case reports received by DACA in a period of six 
years (2002 – 2007GC). All cases reported over the study period were included for analysis. Descriptive analysis was 
carried out to estimate the prevalence of adverse drug reactions and to assess their trend over the study period. To 
assess the strengths and weakness of the ongoing national ADRM, cases were analyzed by their location, time of 
occurrence, type of the health professional who made the case reports, drugs implicated, clinical manifestations and 
age of subjects affected.  
Results: A total of 249 ADR cases were reported between 2002 and 2007. An average of 0.5 ADR cases per million 
populations were reported annually. The majority (36%) of all the cases were for 31 to 40 years of age. Cases were 
reported mainly (63%) from health facilities in the capital city. Physicians made 76% of all cases reported. 
Antiretroviral drugs were implicated in 70% of the cases reported. The most widely adverse events reported were 
dermatological disorders. 
Conclusions:  The level of ADR case reporting is very low showing the need to address major constraints of ongoing 
ADR monitoring. Thus, comprehensive measures aimed at improving under-reporting and effectiveness of ADRM 
should be instituted.  [Ethiop. J. Health Dev.  2011;25(2):168-173] 
 
Introduction 
Lack of a system for monitoring drug safety is a major 
problem contributing to poor health in Ethiopia and other 
sub-Saharan countries. While demand for modern 
pharmaceuticals is increasing, parallel measures to ensure 
their safety are lacking (1-2).  
 
It is known that different classes of adverse events might 
be displayed when drugs are exposed to different 
environmental and genetic influences (3-4).  Studies have 
shown that the Ethiopian population has a distinct genetic 
makeup compared to Caucasian, Oriental or other Black 
populations (5).  Monitoring the safety of these drugs 
contributes to building evidence on the safety of 
medicines pertinent to the Ethiopian population. ADRs 
increase morbidity, mortality and the cost of health care; 
however, ADR related morbidities are mostly avoidable 
(6-7).  Monitoring ADRs helps reduce hospital 
admissions; and it saves substantial amount of financial 
and human resources which could be spent on patient 
treatment (9-11).  It also contributes to detecting 
substandard and counterfeit medications (12-13). 
A department for monitoring ADRs in Ethiopia was 
launched in 2002. However, little or no attempt was 
made to assess how the monitoring system functions in 
terms of ADR case detection and actions taken to 
improve it. We therefore assessed the patterns of ADR 
reporting to DACA from 2002 to 2007 GC and suggest 
some improvements in the ADRM system in Ethiopia. 
 
Methods 
Study design: This is a retrospective analysis of the 
national ADR case reports.   DACA collects cases using 
adverse drug reactions reporting forms from public health 
facilities.  As part of a routine, health professionals are 
expected to report cases with ADRs to DACA.  The 
surveillance relies on voluntary spontaneous reporting of 
ADR cases by health professionals to DACA. 
 
Data collection: For the purpose of this study, we took 
retrospective data of adverse drug reaction reports 
received by DACA during a period of six years (2002-
2007GC).  
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Study variables:  This study included ADR reports on 
commonly used drugs in primary and secondary care 
including antitubercular, antiretrovirals, antifungals, 
antibiotics and analgesics.  
 
Data analysis: Descriptive analysis was made using 
SPSS (version 12). Cases were analyzed based on: (i) 
their geographical area or location; (ii) their age group; 
(iii) time of occurrence; (iv) the health professional  who 
reported cases (v) the drug implicated; and (vi) ADR 
manifestations.  The prevalence of ADR was calculated 
for new cases with ADR per million population per year.  
 
In relative terms, a large number of ADRs were received 
from the capital, Addis Ababa. Of the total cases 
detected, 156 (63%) were from the capital city while the 
remaining 82 (33%) were from other parts of the country. 
 
Of the total reported ADR cases, 221 (95%) were in the 
age group 11 to 60 while 84 (36%) were between 31 to 
40 years (Figure 1). There was no case report received 
for the age group less than one year. 
 
The number of ADR cases reported to DACA has shown 
an increasing trend since 2002, with the exception of 





Figure 1: Distribution of ADR case reports by their age group. 
 
The number of ADR cases reported to DACA has shown 
an increasing trend since 2002, with the exception of 
2005 (Figure 2).  A relatively marked increase in ADR 
reporting by HPs was recorded during the years 2006 and 
2007.  
 
Figure 3 depicts the proportion of ADR cases reported by 
types of health professionals. Most cases were detected 
and reported to DACA by physicians; 185 (76%).  
Druggists, pharmacy workforces who have a diploma 
qualification in pharmacy, detected 39 (16%) of the total 




Figure 2: ADR case reports received by year 
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Figure 3: The type of health professionals reporting ADR cases 
 
 
Table 1 shows the type of drugs implicated and the 
physiological systems affected by adverse events.   Over 
173 (70%) of ADR cases were reported for antiretroviral 
drugs, followed by antibiotics and anti-tubercular drugs.  
Reported manifestations of adverse events include 
dermatological 83 (34%), nervous system 70 (29%) and 
cardiovascular 36 (15%). 
 
Table 1: Drugs groups implicated for ADR and 
physiological systems affected. 














































This study showed that the level of ADR under reporting 
is alarmingly low. The level of ADR monitoring is much 
higher in many other countries (14).  The relatively low 
response of HPs outside the capital Addis Ababa could 
be attributed to a number of factors; namely poor access 
to medical information and lack of enough awareness and 
training programs. The high number of incomplete ADR 
case reports 11(4.5%) showed the low quality of the 
ADR reports. 
 
There are no reports received for age groups under one 
and a small number of case reports were received for 
those who are 60 and over. Although the two groups are 
highly vulnerable to adverse events of drugs, the small 
number of ADR cases reports received shows the 
inadequate attention given to these groups. An increasing 
trend of ADR reporting to DACA were observed except 
in 2005. DACA’s ADR awareness training programmes 
given to HPs for different HPs could be a factor in the 
relatively larger increase in ADR case reports received 
between 2006 and 2007. The main reason for decline in 
2005 is not clear. 
 
The low level of ADR reporting within the public health 
system could be attributed to several factors including 
poor quality of training of HPs, the unavailability of tools 
for reporting, low utilization and poor feedback on ADR 
surveillance reports and low coverage/poor integration at 
low health facilities.  Several studies conducted in other 
countries support the importance of training HPs in 
improving under reporting of ADRs (15,16).  Studies 
also report that training programs can help in changing 
attitudes towards reporting of very serious adverse events 
(17,18).  These studies identified the need for tailoring 
educational programs towards attitudes which act as a 
barrier against ADR reporting. Up to now, no such 
studies were conducted that examined attitude and its 
effects on identification and reporting of ADRs in 
Ethiopia. Training methods, which employ other methods 
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like visual tools, such as using a videotape, have been 
found to have a greater impact than just oral presentation 
(19).  This has been attributed to the graphic nature of 
educational videotapes. 
 
Elsewhere, other reasons identified for under reporting 
by HPs included unavailability of reporting forms and the 
lack of information where to get one (20,21).  Increasing 
the availability of ADR reporting forms within ADR 
bulletins and in prescription pads have been found to 
significantly increase ADR reporting (22).  This was 
attributed to better convenience in obtaining ADR 
reporting forms at practice settings where they are 
required to be completed.  
 
Involvement of all HPs is vital in improving under-
reporting. Active ADR monitoring without the 
involvement of nurses is unlikely to achieve its purpose 
in Ethiopia. They are one of the key players in the health 
care system.  Most of the lower health facilities in 
Ethiopia are staffed with nurses. The fact that nurses 
spend most of their time with patients is an asset in 
monitoring ADRs: this put them in a strategic position to 
detect ADRs. The involvement of nurses in the UK and 
Sweden has resulted in increasing ADR reports (23-24).  
Pharmacists and druggists can potentially contribute to 
ADR monitoring because of their availability in the rural 
parts of the country. The importance of embracing the 
multidisciplinary approach to improve under-reporting of 
ADRs need to be emphasized. Although there is evidence 
in favor of patient ADR reporting, this may be a less 
feasible option from the perspectives of cost and human 
resources (25). 
 
One of the concerns of HPs about ADR reporting is not 
knowing what happened to the ADR report for that which 
they have made an effort and invested time to complete 
(26).  Providing feedback to reporting institutions paves a 
path for further communication. It also builds trust within 
the system and helps to make a rapport with HPs.   As 
such, feedback is indispensable interventions for 
encouraging more and further ADR reporting. They 
convey an impression that reports are taken seriously and 
are contributing towards improving the quality of drug 
safety (27-28).  In addition to serving as a confirmation 
of ADR, receipt and appreciation of their effort in 
reporting, as each acknowledgment is given a reference 
number, it reduces double reporting of a single ADR.  
 
In countries like Ethiopia, where HPs are under intense 
workload, the value of any motivational incentives 
cannot be ignored or undervalued. Lack of interest and 
motivation to report ADRs by HPs is one of the factors 
contributing to under reporting of ADRs. Providing 
incentives such as issuing a certificate for reporting 
ADRs or pens with a reminder logo as recognition for 
participation were shown to improve participation in 
ADR monitoring (29). 
The introduction of antiretroviral drugs is quite recent in 
Ethiopia. Financial support gained through The 
President's Emergency Plan for AIDS Relief (PEPFAR) 
has made the availability of antiretroviral drugs a reality 
to thousands of patients (30). The fact that antiretroviral 
drugs, implicated in most ADRs received by DACA, 
shows the need for active pharmaco-vigilance system for 
newly licensed medicines in Ethiopia. A study done at St. 
Paul’s Hospital in Addis Ababa has showed an increased 
risk of Nevirapine associated skin rash on HIV\AIDS 
female patients; and stressed the need for appropriate 
education for patients and HPs for the appropriate 
management of ADRs (31). 
 
Most of these ADR cases reported to DACA were 
primarily based on direct clinical observations of 
patients.  But, hematological adverse events which need 
laboratory results for accurate description of ADRs like 
agranolocytosis are not being reported to DACA. Blood 
disorders associated with the usage of drugs like oral 
chloramphenicol and dipyron injection are still widely 
practiced in Ethiopia. These drugs are still in use despite 
the fact that they had been banned from many countries 
because of their associated life threatening blood disorder 
(32, 33).  Thus, harm caused by these drugs will still 
continue in Ethiopia unless surveillance and diagnostic 




This study used retrospective case reports generated only 
in public health facilities. Consequently, the magnitude 
of ADR cases can be under-estimated because of 
exclusion of patients who consulted private practitioners 
over the study period. The other limitation is that the 
findings of the study may not reflect current status of 
cases with ADRs and its monitoring system. The study 
determined under-reporting of ADR cases and suggested 
ways to improve the problem.  But, measures 
recommended need to be specified through more focused 
studies that explain the causes, concerns and difficulties 
faced by health professionals.  
 
Conclusions 
The level of ADR reporting is very low. In order to 
protect the public from avoidable adverse events, 
comprehensive intervention measures to improve under-
reporting and effective surveillance should be instituted. 
These include training of HPs, ensuring the availability 
of reporting forms, encouraging the involvement of all 
HPs, providing feedbacks on ADR case reports and 
disseminating the findings of analysed case reports back 
to health care professionals where it underpins practice. 
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